Want to see AU:OCC full AI Analyst Report?

Orthocell Ltd (OCC) Price & Analysis

79 Followers

OCC Stock Chart & Stats

AU$0.81

AU$0.07(4.58%)

At close: Jan 09 4:00 PM EST

AU$0.81

AU$0.07(4.58%)

Day’s Range― - ―

52-Week RangeAU$0.70 - AU$1.60

Previous CloseN/A

Volume2.26M

Average Volume (3M)820.75K

Market Cap

AU$197.43M

Enterprise ValueAU$162.25M

Total Cash (Recent Filing)AU$44.37M

Total Debt (Recent Filing)AU$835.79K

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Aug 28, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding272,316,530

10 Day Avg. Volume747,972

30 Day Avg. Volume820,745

Financial Highlights & Ratios

PEG Ratio-3.76

Price to Book (P/B)18.08

Price to Sales (P/S)34.89

P/FCF Ratio-29.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$1.19

Price Target Upside46.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.03

Revenue Forecast (FY)AU$22.80M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained top-line growth demonstrates tangible market traction for Orthocell’s products and services. Over the next 2-6 months continued revenue expansion supports scale benefits, helps absorb fixed R&D and manufacturing costs, and creates a pathway for structural margin improvement as commercialization ramps.

Low Financial LeverageA very low debt-to-equity position and healthy equity ratio provide durable balance-sheet flexibility for a capital-intensive biotech. This reduces default risk, preserves capacity to raise non-debt capital, and supports funding clinical development, manufacturing scale-up and commercialization without immediate refinancing pressure.

Free Cash Flow ImprovementAn improvement in free cash flow growth signals better cash conversion or working-capital management versus prior periods. If sustained, this trend meaningfully reduces external funding needs, enables reinvestment into commercialization and trials, and increases the firm’s medium-term financial resilience.

Bears Say

Negative ProfitabilityPersistent negative net and EBIT margins and a negative return on equity indicate the business is not yet profitable. Over months this limits internal funding for R&D and commercial expansion, raises likelihood of dilutive capital raises, and makes sustained shareholder returns contingent on material margin turnarounds.

Negative Operating Cash FlowOngoing negative operating cash flow, despite FCF improvement, means core operations aren’t cash-generative. This structural cash burn forces reliance on external financing or equity issuance, which can constrain timely investment in manufacturing scale-up, distribution and clinical programs over the medium term.

Regulatory And Commercial DependencyOrthocell’s revenue outlook materially depends on approvals, reimbursement decisions, surgeon adoption and partner distribution. These external, often lengthy processes can delay or cap revenue growth, creating persistent execution risk for product-led biotech commercialization over the coming months.

Orthocell Ltd News

Orthocell Issues Cautious Q4 FY26 Investor Presentation Disclaimer

Orthocell Ltd ( ($AU:OCC) ) has shared an update. Orthocell has released a Q4 FY26 investor presentation outlining...

7d ago

OCC

Orthocell hits record revenue as Remplir adoption accelerates and global rollout advances

The latest announcement is out from Orthocell Ltd ( ($AU:OCC) ). Orthocell reported record quarterly revenue of $3.8...

8d ago

OCC

Orthocell to Unveil Quarterly Results and Detail U.S. Rollout of Remplir

Orthocell Ltd ( ($AU:OCC) ) has shared an announcement. Orthocell Ltd has scheduled the release of its quarterly...

15d ago

OCC

Orthocell Expands Humanitarian Use of Remplir Nerve Repair Device in Ukraine

An update from Orthocell Ltd ( ($AU:OCC) ) is now available. Orthocell has expanded the humanitarian deployment of...

21d ago

OCC

Orthocell issues new shares after employee option exercise under equity incentive plan

Orthocell Ltd ( ($AU:OCC) ) has issued an announcement. Orthocell Limited has issued 445,696 fully paid ordinary shares...

3M ago

OCC

Orthocell Seeks ASX Quotation for 445,696 New Shares

Orthocell Ltd ( ($AU:OCC) ) just unveiled an update. Orthocell Ltd has lodged an application with the ASX...

3M ago

OCC

Orthocell logs first Remplir sales in Canada, advancing global nerve repair rollout

An update from Orthocell Ltd ( ($AU:OCC) ) is now available. Orthocell has recorded its first commercial sales...

3M ago

OCC

Orthocell’s Remplir Nerve Repair Device Posts Near-90% Success in Real-World Study

Orthocell Ltd ( ($AU:OCC) ) has provided an update. Orthocell has reported new real-world evidence showing its Remplir...

3M ago

OCC

Orthocell Flags Risks and Confidentiality in Q3 FY26 Investor Briefing

An update from Orthocell Ltd ( ($AU:OCC) ) is now available. Orthocell Ltd, a regenerative medicine and medical...

3M ago

OCC

Orthocell records first U.S. military hospital case for Remplir after DoD–VA approval

The latest update is out from Orthocell Ltd ( ($AU:OCC) ). Orthocell has completed the first U.S. Department...

3M ago

OCC

OCC FAQ

What was Orthocell Ltd’s price range in the past 12 months?

Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.60 in the past 12 months.

What is Orthocell Ltd’s market cap?

Orthocell Ltd’s market cap is AU$197.43M.

When is Orthocell Ltd’s upcoming earnings report date?

Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 39 days.

How were Orthocell Ltd’s earnings last quarter?

Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Orthocell Ltd overvalued?

According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Orthocell Ltd pay dividends?

Orthocell Ltd does not currently pay dividends.

What is Orthocell Ltd’s EPS estimate?

Orthocell Ltd’s EPS estimate is 0.

How many shares outstanding does Orthocell Ltd have?

Orthocell Ltd has 272,316,530 shares outstanding.

What happened to Orthocell Ltd’s price movement after its last earnings report?

Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.

Which hedge fund is a major shareholder of Orthocell Ltd?

Currently, no hedge funds are holding shares in AU:OCC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Orthocell Ltd Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

49.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Orthocell Ltd

Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.

Orthocell Ltd (OCC) Earnings & Revenues

Historic Earnings Reports

OCC Stock 12 Month Forecast

Average Price Target

AU$1.19

▲(46.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"AU$2","-1":"-AU$1","-0.25":"-AU$0.25","0.5":"AU$0.5","1.25":"AU$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$1.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$1.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$1.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.7561538461538462,0.7923076923076923,0.8284615384615385,0.8646153846153846,0.9007692307692308,0.936923076923077,0.9730769230769231,1.0092307692307692,1.0453846153846154,1.0815384615384616,1.1176923076923075,1.1538461538461537,{"y":1.19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.7561538461538462,0.7923076923076923,0.8284615384615385,0.8646153846153846,0.9007692307692308,0.936923076923077,0.9730769230769231,1.0092307692307692,1.0453846153846154,1.0815384615384616,1.1176923076923075,1.1538461538461537,{"y":1.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.72,0.7561538461538462,0.7923076923076923,0.8284615384615385,0.8646153846153846,0.9007692307692308,0.936923076923077,0.9730769230769231,1.0092307692307692,1.0453846153846154,1.0815384615384616,1.1176923076923075,1.1538461538461537,{"y":1.19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.26,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.915,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.795,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >